CRH's $8.5B Infrastructure Bet, AbbVie's $10.9B Immunology Play, SpaceX at $185
About this episode
CRH acquires Arcosa for $8.5 billion in infrastructure consolidation play, AbbVie bets $10.9 billion on next-generation eczema drug Apogee Therapeutics, SpaceX trades near $185 as valuation debate intensifies post-IPO
Chapters
Sources & Citations
CRH to Acquire Arcosa; Leading U.S. Provider of Aggregates and Critical Infrastructure Products for $8.5B (CRH Official Press Release)
www.crh.com
CRH to Acquire Arcosa for $8.5B (Business Wire)
www.businesswire.com
CRH to Acquire Arcosa for $150 Per Share; Secures $5.75 Billion Bridge Financing (TradingView News)
www.tradingview.com
CRH Agreed To Buy Arcosa For $8.5 Billion In Cash — Synergy Math (Finimize)
finimize.com
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio (Official Press Release)
news.abbvie.com
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push | Reuters
www.reuters.com
AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect | Fierce Biotech
www.fiercebiotech.com
Apogee Therapeutics surges 48% premarket; AbbVie gains after deal | CNBC
www.cnbc.com
SpaceX IPO takeaways: SPCX closes at $161, jumping 19% after record debut
www.cnbc.com
SpaceX is worth less than half of its $1.75 trillion IPO target, Morningstar says
www.cnbc.com
SpaceX heads for record $1.78tn float amid fears it is overvalued
www.theguardian.com
SpaceX (SPCX) trading at $185.00, Jun 22, 2026
www.investing.com
Loading transcript…